3D Medicines Inc.
Public3D Medicines Inc. is now publicly traded
The data on this page reflects 3D Medicines Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Dec 15, 2022
Last Round
Private Placement
Jul 21, 2023
Total Funding Raised
$323.86M
Company Overview
3D Medicines Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative immuno-oncology drugs to manage cancer as a chronic disease.
Sector
Healthcare
AI Layer
Application
Keywords
3D Medicines Inc. Comparables
Compare 3D Medicines Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genecast | 74% | |
| Beijing Geneplus Technology | 69% | |
| 求臻医学 | 68% |
3D Medicines Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jul 21, 2023 | ||||
| IPO | Dec 15, 2022 | ||||
| Early Funding | Oct 8, 2020 | ||||
| Early Funding | Nov 23, 2017 |
Key People
Founding team and executive leadership
3D Medicines Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hyde Investment Holding Group | Early Funding |
| China Securities (International) Corporate Finance Company Limited | IPO |
| China International Capital Corporation Hong Kong Securities Limited | IPO |
| Southwest Securities (HK) Brokerage Limited | IPO |
| Efung Capital | IPO, Early Funding |
| China Equity Group | Early Funding |
| Ruiyi Investment | Early Funding |
3D Medicines Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access